Intellia Therapeutics
Clinical trials sponsored by Intellia Therapeutics, explained in plain language.
-
Gene therapy aims to stop painful swelling attacks in rare disease
Disease control OngoingThis study tests a new treatment called NTLA-2002 for people with hereditary angioedema (HAE), a condition that causes sudden, painful swelling attacks. The goal is to see if the drug can reduce the number of attacks compared to a placebo. About 80 participants aged 16 and older …
Phase: PHASE3 • Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated May 17, 2026 12:56 UTC
-
Gene therapy aims to stop painful swelling attacks in rare disease
Disease control OngoingThis study tests a new treatment called NTLA-2002 for adults with hereditary angioedema (HAE), a condition that causes sudden, painful swelling attacks. The therapy uses gene-editing to reduce a protein that triggers attacks. Researchers are checking safety and how well it works …
Phase: PHASE1, PHASE2 • Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Gene therapy for HAE: how does it hold up over time?
Disease control ENROLLING_BY_INVITATIONThis study follows about 100 people who previously received the experimental gene therapy NTLA-2002 for hereditary angioedema (HAE). Researchers will monitor participants for long-term safety and check how well the treatment continues to prevent HAE attacks. The goal is to unders…
Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated May 12, 2026 13:39 UTC